Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
Prevenar 13 is safe for administration to Filipinos.
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Non-interventional Study of the Safety of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) in the Philippines: a Post Marketing Surveillance Study|
- Number of participants reporting adverse events as a measure of safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
|Study Start Date:||December 2011|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
|Prevenar 13 patients||
Biological: Prevenar 13
Prevenar 13 vaccine as prescribed by the physician based on approved product indication
Other Name: Pneumococcal 13-valent Conjugate Vaccine (13vPnC)
Filipino patients prescribed and administered with the vaccine will be monitored for safety Patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.
|Contact: Pfizer CT.gov Call Center||1-800-718-1021|
Show 106 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|